SEC Filing Summary: Healthcare Acquisition Corp. (HAQ)
Business Context and Reporting Period
This Form 8-K was filed by Healthcare Acquisition Corp. (HAQ) on January 24, 2007, reporting events occurring on January 19 and January 23, 2007. HAQ is a Delaware corporation engaged in seeking a business combination, specifically the acquisition of PharmAthene, Inc. The filing addresses clarifications to existing warrant agreements and the execution of a new advisory agreement.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. Specific financial obligations disclosed include:
- Advisory Success Fee: $500,000 payable to Maxim Group LLC upon successful completion of the PharmAthene acquisition.
- Advisory Expenses: Up to $15,000 payable to Maxim Group LLC, regardless of the acquisition's success.
- Trust Fund Status: Maxim Group LLC has waived any claims against HAQ's trust fund related to this agreement.
Material Changes and Agreements
Two primary material agreements were executed or clarified during this period:
- Warrant Clarification and Unit Purchase Option Amendment: HAQ clarified terms with Continental Stock Transfer & Trust Company and Maxim Partners, LLC. The agreements state that if a registration statement is not effective when a holder wishes to exercise a warrant or option, the instrument may expire unexercised. Crucially, HAQ is not obligated to provide cash settlement ("net-cash settle") for these instruments.
- Advisory Agreement: HAQ engaged Maxim Group LLC to advise on the acquisition of PharmAthene, Inc., effective January 19, 2007.
Outlook, Risks, and Management Commentary
Management's focus is on the pending acquisition of PharmAthene, Inc. The filing highlights a specific risk mitigation regarding the Warrant Agreement and Unit Purchase Option: holders cannot force a cash settlement if the securities are not registered for trading at the time of exercise. This limits HAQ's immediate liquidity obligations related to these instruments.
Investor Verification Checklist
- Verify the status of the registration statement for securities issuable upon warrant and option exercise.
- Confirm the progress and expected closing date of the PharmAthene, Inc. acquisition.
- Review the full text of the Warrant Clarification Agreement (Exhibit 4.2) and Advisory Agreement (Exhibit 10.1) for additional covenants.
- Monitor future filings for the payment of the $500,000 success fee contingent on the deal closing.